Login to Your Account



Search

Search results

Pharma: Clinic roundup

Bayer Healthcare , of Whippany, N.J., reported positive results from the PROTECT VIII trial evaluating the company’s investigational long-acting site-specific pegylated recombinant human factor VIII compound BAY 94-9027. (BioWorld-Today-2014 ...

BioWorld Today - Staff - 2014-02-19 01:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• Pfizer Inc. , of New York, said a Phase IIIb withdrawal design study for Lyrica (pregabalin) in patients with inadequately treated painful diabetic peripheral neuropathy did not meet its primary endpoint, defined as the change in mean pain score ...

BioWorld Today - Staff - 2012-05-07 00:00 - 0 comments - 0 attachments

Pharma: Clinic Roundup

• UCB SA , of Brussels, Belgium, reported post-hoc analyses of pivotal trials of Neupro (rotigotine transdermal system) in patients with restless legs syndrome (RLS)/Willis Ekbom disease, showing improvements with rotigotine vs. placebo in most of ...

BioWorld Today - Staff - 2012-04-26 00:00 - 0 comments - 0 attachments

Pharma: clinic roundup

Ipsen SA , of Paris, reported results of the international phase III clinical trial of Dysport Next Generation (DNG), an injectable form of botulinum toxin type A, in cervical dystonia. DNG was clinically and statistically superior to placebo in th ...

BioWorld Today - Staff - 2014-02-06 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Pfizer Inc. , of New York, said the randomized Phase II (PALOMA-1) of palbociclib achieved its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in progression-free survival for the combination of pal ...

BioWorld Today - Staff - 2014-02-04 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Pfizer Inc. , of New York, reported top-line data from two Phase III studies of irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small-cell lung cancer (NSCLC), neither of which met their primary objectives. ...

BioWorld Today - Staff - 2014-01-28 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Pfizer Inc. , of New York, reported top-line results from a Phase III study of ALO-02 (oxycodone hydrochloride/naltrexone hydrochloride extended-release capsules) in patients with moderate to severe chronic low back pain, showing that the drug met th ...

BioWorld Today - Staff - 2014-01-24 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Takeda Pharmaceutical Co. Ltd. , of Osaka, Japan, said Takeda Development Center Shanghai and Takeda Development Center Asia Pte. Ltd., started the Phase III TOURMALINE-MM1 global study with the oral proteasome inhibitor, ixazomib, in relapsed and/or ...

BioWorld Today - Staff - 2014-01-23 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Pfizer Inc. , of New York, said a new smoking-cessation clinical study assessing the efficacy and safety of Chantix/Champix (varenicline) met its primary and secondary endpoints. (BioWorld-Today-2014-01-22) ...

BioWorld Today - Staff - 2014-01-22 01:00 - 0 comments - 0 attachments

Pharma: Clinic roundup

Ipsen SA , of Paris, said the results of the ELECT Phase III trial testing Somatuline Autogel/Somatuline Depot (lanreotide) showed a statistically significant reduction vs. placebo in the number of days in which immediate-release octreotide was used ...

BioWorld Today - Staff - 2014-01-21 01:00 - 0 comments - 0 attachments